JP2019167346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019167346A5 JP2019167346A5 JP2019087445A JP2019087445A JP2019167346A5 JP 2019167346 A5 JP2019167346 A5 JP 2019167346A5 JP 2019087445 A JP2019087445 A JP 2019087445A JP 2019087445 A JP2019087445 A JP 2019087445A JP 2019167346 A5 JP2019167346 A5 JP 2019167346A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- combination
- bacterial cell
- pharmaceutical composition
- penetrating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842749P | 2013-07-03 | 2013-07-03 | |
| US61/842,749 | 2013-07-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Division JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019167346A JP2019167346A (ja) | 2019-10-03 |
| JP2019167346A5 true JP2019167346A5 (enExample) | 2019-12-26 |
Family
ID=52144163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Active JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
| JP2019087445A Pending JP2019167346A (ja) | 2013-07-03 | 2019-05-07 | 抗癌組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524319A Active JP6896420B2 (ja) | 2013-07-03 | 2014-07-01 | 抗癌組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11141492B2 (enExample) |
| EP (1) | EP3016716B1 (enExample) |
| JP (2) | JP6896420B2 (enExample) |
| KR (1) | KR20160027971A (enExample) |
| CN (1) | CN105407974A (enExample) |
| AU (1) | AU2014284396A1 (enExample) |
| BR (1) | BR112015033053A2 (enExample) |
| CA (1) | CA2917102A1 (enExample) |
| IL (1) | IL243323A0 (enExample) |
| WO (1) | WO2015002969A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519734D0 (en) | 2015-11-09 | 2015-12-23 | Univ Swansea | Cancer therapy |
| WO2018055014A1 (en) * | 2016-09-23 | 2018-03-29 | Ventana Medical Systems, Inc. | Methods and systems for scoring extracellular matrix biomarkers in tumor samples |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| CA3176812A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| US20220193149A1 (en) * | 2019-05-16 | 2022-06-23 | City Of Hope | Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery |
| JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム |
| CN113769063B (zh) * | 2021-09-30 | 2024-01-19 | 浙江大学 | 一种多肽ptpr在制备肿瘤免疫治疗药物中的应用 |
| KR102680316B1 (ko) * | 2021-11-01 | 2024-07-01 | 오토텔릭바이오 주식회사 | 안티센스 올리고뉴클레오타이드 |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖ｒｎａ仲介遺伝子抑制 |
| US20090123367A1 (en) * | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| WO2005018332A1 (en) * | 2003-08-13 | 2005-03-03 | The General Hospital Corporation | Modified microorganisms for anti-cancer therapy |
| EP1986697B1 (en) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| CN1974759B (zh) * | 2006-07-26 | 2010-06-09 | 吉林大学 | 运载重组质粒的减毒沙门氏菌及其在抗肿瘤中的应用 |
| EP2081949B1 (en) | 2006-09-22 | 2014-12-10 | GE Healthcare Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| EP2173875B1 (en) * | 2007-06-15 | 2017-08-30 | Cequent Pharmaceuticals, Inc. | Bacteria mediated gene silencing |
| WO2009128917A2 (en) | 2008-04-14 | 2009-10-22 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| WO2012149364A1 (en) * | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
-
2014
- 2014-07-01 CA CA2917102A patent/CA2917102A1/en not_active Abandoned
- 2014-07-01 BR BR112015033053A patent/BR112015033053A2/pt not_active Application Discontinuation
- 2014-07-01 EP EP14819900.3A patent/EP3016716B1/en active Active
- 2014-07-01 CN CN201480041314.4A patent/CN105407974A/zh active Pending
- 2014-07-01 JP JP2016524319A patent/JP6896420B2/ja active Active
- 2014-07-01 WO PCT/US2014/045086 patent/WO2015002969A1/en not_active Ceased
- 2014-07-01 KR KR1020167001786A patent/KR20160027971A/ko not_active Withdrawn
- 2014-07-01 AU AU2014284396A patent/AU2014284396A1/en not_active Abandoned
-
2015
- 2015-12-22 US US14/978,590 patent/US11141492B2/en active Active
- 2015-12-24 IL IL243323A patent/IL243323A0/en unknown
-
2019
- 2019-05-07 JP JP2019087445A patent/JP2019167346A/ja active Pending
-
2021
- 2021-09-17 US US17/478,133 patent/US20220241432A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530233A5 (enExample) | ||
| JP5070051B2 (ja) | 癌を治療するための細菌組成物 | |
| JP6731405B2 (ja) | ウイルス粒子を用いた癌免疫療法 | |
| JP2017523187A5 (enExample) | ||
| US20220275099A1 (en) | Administration of kynurenine depleting enzymes for tumor therapy | |
| JP2019532047A (ja) | 癌を処置するためのアデノウイルスとチェックポイント阻害剤の組合せ | |
| Li et al. | Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy | |
| Chen et al. | Triptolide modulates tumour-colonisation and anti-tumour effect of attenuated Salmonella encoding DNase I | |
| CN106540256A (zh) | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 | |
| CN104473973B (zh) | 一株戈氏梭菌驯化株的应用 | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Xiao et al. | An immunometabolic patch facilitates mesenchymal stromal/stem cell therapy for myocardial infarction through a macrophage‐dependent mechanism | |
| KRzyKawsKi | Combined bacterial and viral treatment: a novel anticancer strategy | |
| Lam et al. | Targeting mesenchymal stem cell therapy for severe pneumonia patients | |
| CN114632149A (zh) | 溶瘤病毒和免疫调节剂在协同抑制晚期肝癌中的应用 | |
| CN107007830B (zh) | 一种无毒株弓形体和中药多糖佐剂组合物的用途、疫苗及制备方法 | |
| Kawano et al. | New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin | |
| WO2020094865A1 (fr) | Utilisation du microrna mir-27a-5p pour traiter l'inflammation intestinale induite par clostridium difficile | |
| CN113117088B (zh) | 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用 | |
| Pisano et al. | Updates on intravesical therapy | |
| EP0644773B1 (fr) | Complexe immunomodulateur anti-sida | |
| Zheng | Engineered outer membrane vesicles enhance solid tumor CAR-T cell therapy | |
| US20110144031A1 (en) | Pharmaceutical composition for inducing damages of endothelial cells and treating tumor and method for treating tumor by using the same | |
| Fialho et al. | Recent patents on bacterial proteins as potential anticancer agents | |
| JP2023550043A5 (enExample) |